https://charts.traderzeitung.de/phases/US00461U1051
string(1399) "{"isin":"US00461U1051","name":"Aclaris Therapeutics Inc","stock_id_xnas":7873092,"stock_id_xnys":null,"generated_at":"2026-08-21 03:00:00","days":[{"date":"2026-08-18","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.31,"close_at":"2026-08-18 21:59:00","complete":true,"perf_pct":null},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-19","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.435,"close_at":"2026-08-19 21:59:00","complete":true,"perf_pct":1.981},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]},{"date":"2026-08-20","dst_offset":6,"phases":[{"phase":1,"label":"pre","from":"10:00","to":"15:30","close":null,"close_at":null,"complete":true,"perf_pct":null},{"phase":2,"label":"regular","from":"15:30","to":"22:00","close":6.325,"close_at":"2026-08-20 21:59:00","complete":true,"perf_pct":-1.7094},{"phase":3,"label":"post","from":"22:00","to":"26:00","close":null,"close_at":null,"complete":true,"perf_pct":null}]}]}"
Aclaris Therapeutics Aktie News & Nachrichten

Aclaris Therapeutics Aktie News & Nachrichten

[WKN: A1412H | Symbol: ACRS]
Realtimekurs
   
Vorbörsliche Indikationen
Regulärer Handel
Nachbörslicher Handel

Artikel aus der Redaktion der Trader-Zeitung

Aclaris Therapeutics: Zukunftsperspektiven im Bereich der Immunentzündungskrankheiten - Guggenheim empfiehlt den Kauf und sieht ein Potenzial von 159 %!

Strategische Ausrichtung und Kernkompetenzen Aclaris Therapeutics (ACRS) ist ein biopharmazeutisches...

TOP-5-Kursziele der Analysten am 19.11.24

Aclaris Therapeutics [US00461U1051]: BTIG nimmt Hochstufung von "Hold" auf "Buy" mit Kursziel 8 USD vor...

  • 1
MT Newswires 06.08.2026 13:35 Uhr

-- Earnings Flash (ACRS) Aclaris Therapeutics, Inc. meldet Q2-Umsatz von 1,6 Mio. $, verglichen mit der FactSet-Schätzung von 1,4 Mio. $

07:16 AM EDT, 06.08.2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid

MT Newswires 06.08.2026 13:04 Uhr

Earnings Flash (ACRS) Aclaris Therapeutics verzeichnet im Q2 einen Nettoverlust von 0,15 USD je Aktie, verglichen mit der FactSet-Schätzung von 0,16 USD Verlust

07:03 AM EDT, 08/06/2026 (MT Newswires) -- http://www.mtnewswires.com Copyright © 2026 MT Newswires. All rights reserved. MT Newswires does not provid